M 2 HepPrEP: study protocol for a multi-site multi-setting randomized controlled trial of integrated HIV prevention and HCV care for PWID

Opioid use is escalating in North America and comes with a multitude of health consequences, including HIV and hepatitis C virus (HCV) outbreaks among persons who inject drugs (PWID). HIV pre-exposure prophylaxis (PrEP) and HCV treatment regimens have transformative potential to address these co-occ...

Ausführliche Beschreibung

Bibliographische Detailangaben

Veröffentlicht in:	Trials 2022-04, Vol.23 (1), p.341
Hauptverfasser:	Martel-Laferrière, Valérie, Feaster, Daniel J, Metsch, Lisa R, Shackman, Bruce R, Loignon, Christine, Nosyk, Bohdan, Tookes, Hansel, Behrends, Czarina N, Arruda, Nelson, Adigun, Oluleye, Goyer, Marie-Eve, Kolber, Michael A, Mary, Jean-Francois, Rodriguez, Allan E, Yanez, Iveth G, Pan, Yue, Khemiri, Rania, Gooden, Lauren, Sako, Aïssata, Bruneau, Julie
Format:	Artikel
Sprache:	eng
Schlagworte:	Analgesics, Opioid - therapeutic use Drug Users Hepacivirus Hepatitis C - diagnosis Hepatitis C - drug therapy Hepatitis C - prevention & control HIV Infections - diagnosis HIV Infections - drug therapy HIV Infections - prevention & control Humans Multicenter Studies as Topic Pharmaceutical Preparations Randomized Controlled Trials as Topic Substance Abuse, Intravenous - complications Substance Abuse, Intravenous - drug therapy
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!